<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">26298795</PMID>
<DateCompleted>
<Year>2016</Year>
<Month>06</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1878-5506</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>16</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2015</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Sleep medicine</Title>
<ISOAbbreviation>Sleep Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study.</ArticleTitle>
<Pagination>
<MedlinePgn>1160-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sleep.2015.06.015</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1389-9457(15)00834-5</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">At present, there is no consensus regarding how to medically manage chronic insomnia in the long term. The unstated standard of practice is for patients to use hypnotics intermittently. The present study aimed to compare a partial reinforcement strategy with nightly and intermittent dosing strategies for its potential as a maintenance therapy.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A mixed model was used in the study. One between-subjects factor: group (n = 4). One repeated-measures factor: time (12 weekly assessments). A total of 74 subjects with chronic Insomnia were treated with 10 mg zolpidem for 4 weeks. Treatment respondents were randomized to nightly dosing with 10 mg or 5 mg (QHS-10 and QHS-5), intermittent dosing with 10 mg (IDS-10 [3-5 days weekly]), or partial reinforcement dosing with 10 mg (PRS-10 [nightly pill use with 50% active medication and 50% placebos]) for 12 weeks.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">It was found, in compliant subjects (n = 55), that all four strategies evaluated maintained treatment response over time (ie, prevented or delayed relapse). For the subjects that remained in remission, the subjects in the intermittent dosing group (IDS-10) group exhibited poorer sleep continuity.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">While best considered a preliminary study, the present findings suggest that the partial reinforcement strategy may be a viable means toward maintaining treatment gains over time with less active medication.</AbstractText>
<CopyrightInformation>Copyright © 2015. Published by Elsevier B.V.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Perlis</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA; Center for Sleep and Circadian Neurobiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; School or Nursing, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: mperlis@upenn.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Grandner</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA; Center for Sleep and Circadian Neurobiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zee</LastName>
<ForeName>Jarcy</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bremer</LastName>
<ForeName>Erin</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Whinnery</LastName>
<ForeName>Julia</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Barilla</LastName>
<ForeName>Holly</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Andalia</LastName>
<ForeName>Priscilla</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gehrman</LastName>
<ForeName>Phil</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA; Center for Sleep and Circadian Neurobiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Morales</LastName>
<ForeName>Knashawn</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Thase</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA; Mood and Anxiety Disorders Treatment and Research Program, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bootzin</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Psychology, University of Arizona, Tucson, AZ, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ader</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Department of Psychiatry, University of Rochester, Rochester, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K23 HL110216</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 AT003332</GrantID>
<Acronym>AT</Acronym>
<Agency>NCCIH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R21 ES022931</GrantID>
<Acronym>ES</Acronym>
<Agency>NIEHS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01AT003332</GrantID>
<Acronym>AT</Acronym>
<Agency>NCCIH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2015</Year>
<Month>07</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Sleep Med</MedlineTA>
<NlmUniqueID>100898759</NlmUniqueID>
<ISSNLinking>1389-9457</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7K383OQI23</RegistryNumber>
<NameOfSubstance UI="D000077334">Zolpidem</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Sleep Med. 2017 Apr;32:266</RefSource>
<PMID Version="1">28041719</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006993">Hypnotics and Sedatives</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055118">Medication Adherence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011725">Pyridines</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007319">Sleep Initiation and Maintenance Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000077334">Zolpidem</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Insomnia</Keyword>
<Keyword MajorTopicYN="N">Maintenance therapy</Keyword>
<Keyword MajorTopicYN="N">Partial reinforcement</Keyword>
<Keyword MajorTopicYN="N">Placebos</Keyword>
<Keyword MajorTopicYN="N">Zolpidem</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2015</Year>
<Month>02</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2015</Year>
<Month>06</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2015</Year>
<Month>06</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2015</Year>
<Month>8</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2015</Year>
<Month>8</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2016</Year>
<Month>6</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">26298795</ArticleId>
<ArticleId IdType="pii">S1389-9457(15)00834-5</ArticleId>
<ArticleId IdType="doi">10.1016/j.sleep.2015.06.015</ArticleId>
<ArticleId IdType="pmc">PMC4709332</ArticleId>
<ArticleId IdType="mid">NIHMS748334</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Sleep Med. 2001 Jul;2(4):297-307</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11438246</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA. 1984 Oct 12;252(14):1905-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6471323</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Sleep. 1991 Dec;14(6):540-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1798888</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Psychosom Med. 2010 Feb;72(2):192-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20028830</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arch Intern Med. 1998 Sep 14;158(16):1789-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9738608</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA. 1984 May 11;251(18):2410-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6142971</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Manag Care. 2007 Nov;13(5 Suppl):S117-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18041871</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pers Assess. 1983 Oct;47(5):531-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6644527</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neuropsychiatry Clin Neurosci. 1996 Spring;8(2):194-201</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9081556</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9881538</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Ethics. 2008 Spring;19(1):58-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18552054</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Sleep Med. 2008 Oct 15;4(5):487-504</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18853708</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Sleep. 2004 Dec 15;27(8):1567-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15683149</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Sleep. 1992 Aug;15(4):376-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1519015</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Psychiatry. 2004 Aug;65(8):1128-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15323600</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2001 May 24;344(21):1594-602</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11372012</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Psychiatry. 2002 Jan;159(1):5-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11772681</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Pharm Des. 2008;14(32):3456-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19075721</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Psychiatry. 2003 Sep 1;54(5):573-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12946886</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Dev Behav Pediatr. 1992 Apr;13(2):124-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1577957</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Psychosom Res. 2004 Feb;56(2):239-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15016584</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur Psychiatry. 2003 Aug;18(5):201-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12927320</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Sleep Med Rev. 2012 Feb;16(1):5-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21596596</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>